Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction

Abstract

clinicaltrials.gov Identifier: NCT01951625.

Novel Therapies for Heart Failure – Where Do They Stand? –

“…Exploratory analyses, however, demonstrated a significant dose-response relationship, as well as greater NT-proBNP reduction with the 10-mg dose than with placebo ( Figure 6). 66 The 10-mg dose was associated with a significantly greater increase in LVEF than placebo (3.7 units vs. 1.5 units; P<0.05) and with a trend towards reductions in clinical events. There were no significant effects of vericiguat on BP, heart rate, renal function or troponin.…”

Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm

“…Recently, the Soluble Guanylate Cyclase Stimulator in Heart Failure Study (in patients with LVEF <45%) trial, a randomized‐controlled, multicentre double‐blind trial to assess the tolerability and optimal dose of vericiguat in 456 patients with HFrEF, confirmed tolerability but failed to show a significant decrease in NT‐proBNP in the treatment groups (the primary endpoint). There was, however, a demonstrable dose–response relationship for the reduction in NT‐proBNP ( P  < 0.02), which was promising and requires further elucidation (Gheorghiade et al ., 2015). …”

Newer drugs for heart failure: hype or hope?

“…The initial concern for precipitating ischemia was alleviated by an exercise study [12], phase III is being launched at the present time. The authors then detail the mechanisms of the soluble guanylate cyclase (sGC) stimulator vericiguat and summarize the findings of the SOCRATES-REDUCED trial [13] in which compared to placebo vericiguat showed a significant reduction of NT-proBNP with the 10 mg dose of vericiguat. [13] A phase III the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial is being launched and it will determine the role of this drug in the management of HFrEF.…”

“…The authors then detail the mechanisms of the soluble guanylate cyclase (sGC) stimulator vericiguat and summarize the findings of the SOCRATES-REDUCED trial [13] in which compared to placebo vericiguat showed a significant reduction of NT-proBNP with the 10 mg dose of vericiguat. [13] A phase III the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial is being launched and it will determine the role of this drug in the management of HFrEF. The authors then discuss finerenone the nonsteroidal mineralocorticoid receptor antagonist that has superior cardiac selectivity as compared to spironolactone and eplerenone.…”